Soluble CD163 as a Biomarker of Liver Fibrosis and Inflammation in Liver Transplant Recipients.

ABSTRACT:

Background and aims

Post liver transplantation (LT) inflammation and fibrosis are clinical challenges that may affect long-term outcomes. We aimed to investigate sCD163 as a biomarker of liver fibrosis in LT recipients and compare it with the Fibrosis 4 (FIB-4) score and FibroScan.

Methods

In the Danish Comorbidity in Liver Transplant Recipients study (DACOLT) we included 105 LT recipients at Aarhus University Hospital. We reviewed patient records and collected plasma for measurements of sCD163 and FIB-4. Liver stiffness was assessed using FibroScan. Liver biopsies performed <6 months before or after inclusion (n = 33) were investigated by the Banff score and the METAVIR fibrosis score.

Results

The majority (86%) had FibroScan with transient elastography <8 kPa. Plasm

SUBMITTER: Lauridsen EHE 

PROVIDER: S-EPMC12857604 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature